Retrospective study on role of mirtazapine for the relief of symptoms of cancer patients, including neuropathic pain.

Retrospective study on role of mirtazapine for the relief of symptoms of cancer patients, including neuropathic pain. - Retrospective study on role of mirtazapine for the relief of symptoms of cancer patients, including neuropathic pain.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016648

Enrollment

Registered

2015-02-26

Start date

2015-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients who have been prescribed any of mirtazapine (Reflex or Remeron) or amitriptyline (Tryptanol), nortriptyline (Noritren), amoxapine (Amoxan), imipramine (Tofranil), clomipramine (Anafranil) and cases complicated by neuropathic pain.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Pain, numbness (STAS-J version symptoms)	—

Secondary

Measure	Time frame
Insomnia, loss of appetite, anxiety, depression (STAS-J version symptoms)	—

Countries

Japan

Contacts

Public ContactTakao Aoyama

Tokyo University of Science Faculty of Pharmaceutical Sciences

t-aoyama@rs.noda.tus.ac.jp04-7121-3659

Outcome results